瑞联新材：终止渭南瑞联制药有限责任公司原料药项目

Core Viewpoint - The company has decided to terminate the raw material drug project of Weinan Ruilian Pharmaceutical Co., Ltd. and will seek new projects with strong profitability and development prospects [1] Financial Summary - As of June 30, 2025, the cumulative investment in the raw material drug project amounted to 179 million yuan [1] - The total amount of contracts signed but pending payment for the project is 6.11 million yuan [1] - The remaining raised funds amount to 216 million yuan, which will be kept in a dedicated account for raised funds management [1] Future Plans - The company aims to utilize the remaining raised funds effectively by finding new projects and will adhere to regulatory requirements for the use of raised funds [1]